Abstract:Background: The development of cancer is accompanied by metabolic reprogramming, and the liver serves as a central hub for lipid transportation. Apigenin, a plant-derived flavonoid, demonstrates potent anticancer properties across various cancer types and exhibits promising potential as a therapeutic agent for cancer treatment. However, there are limited studies focusing on the downstream targets of apigenin. Moreover, there are few reports on the impact of apigenin in lipid metabolism within liver cancer cells. Purpose: The objective is to elucidate the metabolic mechanism underlying the inhibitory effect of apigenin on liver cancer progression, search for downstream targets and provide reliable data support for the clinical trials of apigenin. Methods: Anticancer effects of apigenin were detected at cellular and molecular levels in vitro, and downstream targets of apigenin, especially metabolic pathway genes, were analyzed by transcriptome. Next, the downstream target of apigenin was verified and the biological function of the downstream target was examined. Finally, the downstream target of apigenin was further verified by restoring target gene expression. Results: Cellular molecular experiments showed that Apigenin inhibited the proliferation, migration, invasion and lipid metabolism of hepatocellular carcinoma (HCC) cells. Transcriptome analysis showed apigenin widely regulates histone demethylase, particularly histone H3K4 lysine demethylase 1A (KDM1A). Apigenin treatment inhibited the expression of KDM1A protein and mRNA levels in liver cancer cells, molecular docking predicted the interaction between apigenin and KDM1A. Furthermore, downregulation KDM1A inhibited the proliferation and lipid metabolism of HCC cells, in the same way, overexpressing KDM1A promoted proliferation of HCC cells. Finally, restoring KDM1A expression partially attenuated the effects of apigenin on lipid metabolism in HCC cells. Conclusion: In conclusion, our study provides compelling evidence that apigenin inhibits liver cancer progression and elucidates its mechanism of action in regulating lipid metabolism. Specifically, we find that apigenin suppresses the progression of HCC cells by downregulating genes involved in lipid metabolism. Additionally, our results indicate that KDM1A acts as a downstream target of apigenin in the inhibition of lipid metabolism in HCC. These findings offer experimental support for the potential use of apigenin as a therapeutic agent for liver cancer, highlighting its relevance in future clinical applications.

Apigenin Suppresses Glut-1 And P-Akt Expression To Enhance The Chemosensitivity To Cisplatin Of Laryngeal Carcinoma Hep-2 Cells: An In Vitro Study

Apigenin Inhibits the Proliferation of Adenoid Cystic Carcinoma Via Suppression of Glucose Transporter-1

Anti-proliferation and Chemo-Sensitization Effects of Apigenin on Human Lung Cancer Cells

Anticancer Mechanism of Apigenin and the Implications of GLUT-1 Expression in Head and Neck Cancers

Effect Of Antisense Oligodeoxynucleotides Glucose Transporter-1 On Enhancement Of Radiosensitivity Of Laryngeal Carcinoma

Co-Inhibition Of Glut-1 Expression And The Pi3k/Akt Signaling Pathway To Enhance The Radiosensitivity Of Laryngeal Carcinoma Xenografts In Vivo

Inhibition of GLUT-1 Expression and the PI3K/Akt Pathway to Enhance the Chemosensitivity of Laryngeal Carcinoma Cells in Vitro

Inhibiting GLUT-1 expression and PI3K/Akt signaling using apigenin improves the radiosensitivity of laryngeal carcinoma in vivo

GLUT-1 Sirna Enhances Radiosensitization of Laryngeal Cancer Stem Cells Via Enhanced DNA Damage, Cell Cycle Redistribution, and Promotion of Apoptosis in Vitro and in Vivo.

Shrna Glut-1 Inhibits Cell Viability, Apoptosis and Migration of Laryngeal Carcinoma HEp-2 Cells Through Regulating Beclin-1-mediated Autophagy

The Impact of Hypoxia Improvement on Laryngeal Squamous Cell Carcinoma Chemotherapy

(−)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells

Apigenin Combined With Gefitinib Blocks Autophagy Flux and Induces Apoptotic Cell Death Through Inhibition of HIF-1α, c-Myc, p-EGFR, and Glucose Metabolism in EGFR L858R+T790M-Mutated H1975 Cells

Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.

Luteolin sensitizes the anticancer effect of cisplatin via c-Jun NH2-terminal kinase-mediated p53 phosphorylation and stabilization.

Apatinib Suppresses Tumor Progression and Enhances Cisplatin Sensitivity in Esophageal Cancer Via the Akt/β-catenin Pathway.

Apigenin sensitizes radiotherapy of mouse subcutaneous glioma through attenuations of cell stemness and DNA damage repair by inhibiting NF-κB/HIF-1α-mediated glycolysis

Apigenin inhibits lipid metabolism of hepatocellular carcinoma cells by targeting the histone demethylase KDM1A

GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin

Apigenin suppresses tumor angiogenesis and growth via inhibiting HIF-1α expression in non-small cell lung carcinoma

Ginsenoside Rb1 for overcoming cisplatin-insensitivity of A549/DDP cells in vitro and vivo through the dual-inhibition on two efflux pumps of ABCB1 and PTCH1